Nectar Lifesciences Ltd
Ticker: NECLIFE
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
13.49
Market Cap
302.53
Debt/Equity
0.6087
ROE %
-11.227
PB
0.3164
Promoter %
44.906
Pledge %
44.354
1Y Rev Growth %
-1.395
5Y Rev Growth %
-6.712
NP Margin %
-6.788
NP Margin 5Y Avg %
-2.257
Trading Reference
1M Return %
-15.652
6M Return %
-40.625
1Y Return %
-64.036
% Away 52W High
229.207
% Away 52W Low
3.372
Daily Volume
174688
Investment Verdict
Risky
Score 56/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 7/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Nectar Lifesciences Ltd is currently trading near a key support level, with recent volume indicating accumulation. If the stock breaks above the resistance level established at the recent high, it could see a potential upside. However, if it fails to hold the support, a downside risk is present.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
A
Aditya BSL Gold ETF
Aditya BSL Gold ETF presents a decent investment opportunity with stable growth potential, though investors should be cautious of governance and execution risks.
View details
S
Saraswati Saree Depot Ltd
Saraswati Saree Depot Ltd shows potential but faces challenges in growth and market sentiment.
View details
A
Almondz Global Securities Ltd
The stock shows potential but is hindered by inconsistent growth and profitability metrics. Caution is advised for new investments.
View details
J
Jainam Ferro Alloys (I) Ltd
Jainam Ferro Alloys (I) Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
M
Menon Pistons Ltd
Menon Pistons Ltd shows potential but faces challenges in growth consistency and valuation. Caution is advised.
View details
E
E Factor Experiences Ltd
E Factor Experiences Ltd presents several risks with inconsistent growth and weak profitability metrics, making it a risky investment at this time.
View details
M
Monarch Surveyors & Engineering Consultants Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
H
Hitech Corporation Ltd
Hitech Corporation Ltd shows potential but faces significant risks and challenges in growth and market sentiment.
View details
A
Aion-Tech Solutions Ltd
Aion-Tech Solutions Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
E
ELGI Rubber Co Ltd
ELGI Rubber Co Ltd shows potential for growth but faces several challenges that could impact its performance.
View details
D
Diamines and Chemicals Ltd
Diamines and Chemicals Ltd shows potential for growth but faces several risks that could impact its performance.
View details
Q
Quest Capital Markets Ltd
Quest Capital Markets Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
P
Prizor Viztech Ltd
Prizor Viztech Ltd shows potential in a future-ready sector but faces significant risks in growth and profitability, making it a risky investment at this time.
View details
A
Alufluoride Ltd
Alufluoride Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised due to execution risks.
View details
Y
Yash Optics & Lens Ltd
Yash Optics & Lens Ltd shows potential in a growing sector but faces challenges in profitability and valuation. Caution is advised.
View details
P
Phantom Digital Effects Ltd
Phantom Digital Effects Ltd shows potential in a growing sector, but faces challenges in execution and valuation metrics.
View details
Business Overview
Nectar Lifesciences Ltd is a leading player in the pharmaceutical and biotechnology sectors in India, specializing in the production of high-quality active pharmaceutical ingredients (APIs) and formulations. Catering to both domestic and international markets, the company is committed to innovation and excellence in healthcare. With a strong focus on quality and compliance, Nectar Lifesciences is positioned to address the growing demand for effective healthcare solutions.
- Established leader in pharmaceuticals and biotechnology
- Specializes in active pharmaceutical ingredients (APIs)
- Strong commitment to quality and compliance
- Catering to both domestic and international markets
- Innovative solutions for healthcare needs
Investment Thesis
Nectar Lifesciences Ltd stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. With a solid foundation and future growth potential, it presents a compelling investment opportunity for retail investors.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services, tapping into evolving market trends.
- Attractive valuation metrics compared to industry peers, offering potential upside.
- Diversified product portfolio positions the company well in the healthcare sector.
- Strong financial performance and strategic initiatives indicate sustainable growth.
Opportunity vs Risk
Opportunities
- Growing demand for honey products
- Expansion into international markets
- Strong brand recognition in India
- Increasing health awareness among consumers
Risks ⚠️
- Regulatory changes affecting production
- Fluctuating raw material costs
- Intense competition in the sector
- Dependence on seasonal sales trends
Peer Perspective
Nectar Lifesciences Ltd trades at a discount compared to peers like Aarti Drugs and Granules India, primarily due to margin pressures. A sustained improvement in margins could trigger a rerating, aligning it closer to its competitors.
Future Outlook
Nectar Lifesciences Ltd is well-positioned for growth, driven by strong market demand and innovative product offerings; however, successful execution and cost control will be crucial to fully realize this potential.
AI FAQs for Retail Users
- Q: What does Nectar Lifesciences Ltd do?A: Nectar Lifesciences Ltd specializes in manufacturing and exporting pharmaceutical and herbal products.
- Q: Is Nectar Lifesciences Ltd a profitable company?A: Profitability can vary; check their latest financial reports for current performance.
- Q: What are the risks of investing in this stock?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Nectar Lifesciences Ltd?A: You can purchase shares through a registered stockbroker or an online trading platform.
- Q: What is the company's growth potential?A: Growth potential depends on market conditions, product demand, and company strategy.
📊 Stock Investment Checklist (100 Points)
Nectar Lifesciences Ltd • Updated: 2025-09-17 04:05:29
-
10BusinessHighThe sector is growing due to increasing demand for pharmaceutical products, but competition is high.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are acceptable, but OCF has shown variability.
-
8ValuationHighP/E and P/B ratios are higher than industry averages, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios are on the lower side.
-
6GovernanceGoodPromoter holding is decent, but there are concerns about pledging.
-
5DriversGoodGrowth catalysts exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral, with low liquidity affecting price action.
Final Score & Verdict
Score 68 / 100
• Decent
Nectar Lifesciences Ltd shows potential in a growing sector, but faces challenges in consistency and valuation, warranting cautious observation.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 68/100